Mariam Nawas to Humans
This is a "connection" page, showing publications Mariam Nawas has written about Humans.
Connection Strength
0.370
-
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797.
Score: 0.030
-
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML. Blood Adv. 2024 02 13; 8(3):553-561.
Score: 0.030
-
Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy. Blood Adv. 2023 08 22; 7(16):4475-4478.
Score: 0.029
-
Linking Body Composition and Nutritional Status with CAR T-cell Efficacy. Cancer Immunol Res. 2023 06 02; 11(6):704.
Score: 0.028
-
Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation. Blood Adv. 2022 11 22; 6(22):5898-5907.
Score: 0.027
-
CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis. Bone Marrow Transplant. 2022 07; 57(7):1101-1107.
Score: 0.026
-
Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. Transplant Cell Ther. 2021 05; 27(5):438.e1-438.e6.
Score: 0.024
-
Serial comprehensive geriatric and quality of life assessments in adults age = 50 years undergoing autologous hematopoietic cell transplantation. J Geriatr Oncol. 2021 05; 12(4):531-539.
Score: 0.023
-
The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. Blood Rev. 2021 03; 46:100744.
Score: 0.023
-
Pilot Study of Telehealth Evaluations in Patients Undergoing Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 06; 26(6):e135-e137.
Score: 0.022
-
Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 06; 25(6):1218-1224.
Score: 0.021
-
A Protean Protein. J Hosp Med. 2019 02 01; 14(2):117-122.
Score: 0.021
-
Complicated necrotizing otitis externa. Am J Otolaryngol. 2013 Nov-Dec; 34(6):706-9.
Score: 0.014
-
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia. Bone Marrow Transplant. 2025 Feb; 60(2):135-143.
Score: 0.008
-
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
Score: 0.008
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
Score: 0.007
-
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
Score: 0.007
-
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
Score: 0.007
-
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
Score: 0.007
-
The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia. JCO Oncol Pract. 2023 02; 19(2):74-85.
Score: 0.007